AI entity
BARDA is most often covered alongside DeepView System, which appears in 2 of these 2 stories. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
BARDA is most often covered alongside DeepView System, which appears in 2 of these 2 stories. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. The 6 average consequence score is below the beat benchmark of 6.7 in the same window. We currently track 2 AI stories that mention BARDA, published between March 19, 2026 and March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 215 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BARDA. Shared-story counts are live from our verified record — not editorial picks.
Data Collection Completion
Expected completion of clinical data collection for burn applications.
Regulatory Submission
Target window for potential FDA submission for DeepView System clearance.
Clinical Study Expansion
Commencement of expanded clinical validation studies for burn care.
Q4 Earnings Release
Spectral AI reports Q4 revenue beat and introduces 2026 revenue guidance.
BARDA Award
Company receives $31.7 million in non-dilutive funding for the DeepView System.
Fiscal Year End
Spectral AI closes FY2025 with $19.7M in R&D revenue and $15.4M in cash.
Spectral AI reported a significant Q4 2025 earnings beat with revenue of $3.8 million and a surprise GAAP profit, bolstered by a recent $31.7 million BARDA award. The company has introduced its first revenue guidance for 2026, marking a critical transition from R&D to commercial-scale medical AI diagnostics.
Spectral AI has been awarded $31.7 million in additional funding from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development and clinical validation of its DeepView® System. This non-dilutive capital will support the company's efforts to bring AI-driven diagnostic precision to burn and wound care, particularly for mass casualty scenarios.
BARDA is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
